[1]杨文慧.重组人血管内皮抑制素联合TP方案对非小细胞肺癌患者肺功能及血气指标的影响[J].医学信息,2022,35(04):162-164.[doi:10.3969/j.issn.1006-1959.2022.04.043]
　YANG Wen-hui.Effects of Recombinant Human Endostatin Combined with TP Regimen on Pulmonary Functionand Blood Gas Indexes in Patients with Non-small Cell Lung Cancer[J].Medical Information,2022,35(04):162-164.[doi:10.3969/j.issn.1006-1959.2022.04.043]
点击复制

重组人血管内皮抑制素联合TP方案对非小细胞肺癌患者肺功能及血气指标的影响()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
35卷
期数:
2022年04期
页码:
162-164
栏目:
药物与临床
出版日期:
2022-02-15

文章信息/Info

Title:
Effects of Recombinant Human Endostatin Combined with TP Regimen on Pulmonary Functionand Blood Gas Indexes in Patients with Non-small Cell Lung Cancer
文章编号:
1006-1959（2022）04-0162-03
作者:
杨文慧
天津港口医院呼吸内科，天津 300456
Author(s):
YANG Wen-hui
Department of Respiratory Medicine,Tianjin Port Hospital,Tianjin 300456,China
关键词:
非小细胞肺癌; 重组人血管内皮抑制素; TP化疗; 肺功能; 血气指标
Keywords:
Non-small cell lung cancer; Recombinant human endostatin; TP chemotherapy; Lung function; Blood gas index
分类号:
R734.2
DOI:
10.3969/j.issn.1006-1959.2022.04.043
文献标志码:
A
摘要:
目的 分析重组人血管内皮抑制素联合TP方案对非小细胞肺癌（NSCLC）患者肺功能及血气指标的影响。方法 选择2019年6月-2021年6月天津港口医院收治的62例NSCLC患者作为研究对象，根据治疗方案不同分为对照组和观察组，每组31例。对照组采用TP方案治疗，观察组在对照组基础上联合重组人血管内皮抑制素治疗，比较两组临床疗效、肺功能指标（PEF、MVV、FEV1）、血清肿瘤标志物（CA125、CEA、VEGF）、血气指标（PaO2、HCO3-）。结果 观察组客观缓解率与疾病控制率高于对照组，差异有统计学意义（P＜0.05）。观察组治疗后PEF、MVV、FEV1、PaO2、HCO3-高于对照组，CA125、CEA、VEGF低于对照组，差异有统计学意义（P＜0.05）。结论 重组人血管内皮抑制素联合TP方案治疗NSCLC疗效肯定，可改善患者肺功能，降低血清肿瘤标志物表达，促进机体血气指标的恢复。
Abstract:
Objective To analyze the effects of recombinant human endostatin combined with TP regimen on lung function and blood gas indexes in patients with non-small cell lung cancer (NSCLC).Methods A total of 62 patients with NSCLC admitted to Tianjin Port Hospital from June 2019 to June 2021 were selected and divided into control group and observation group according to different treatment regimens, with 31 cases in each group. The control group was treated with TP regimen, and the observation group was treated with recombinant human endostatin on the basis of the control group. The clinical efficacy, pulmonary function indexes (PEF, MVV, FEV1), serum tumor markers (CA125, CEA, VEGF), and blood gas indexes (PaO2, HCO3-) were compared between the two groups.Results The objective remission rate and disease control rate in the observation group were higher than those in the control group, the difference was statistically significant (P<0.05). After treatment, PEF, MVV, FEV1, PaO2 and HCO3- in the observation group were higher than those in the control group, CA125, CEA and VEGF were lower than those in the control group, the difference was statistically significant (P<0.05).Conclusion Recombinant human endostatin combined with TP regimen is effective in the treatment of NSCLC, which can improve the lung function of patients, reduce the expression of serum tumor markers and promote the recovery of blood gas indexes.

参考文献/References:

[1]凌敏文,王洁,丁红梓.重组人血管内皮抑制素对非小细胞肺癌患者治疗效果、血管新生、肿瘤细胞增殖及迁移的影响[J].海南医学院学报,2019,25(2):133-136,140.[2]毕军军.重组人血管内皮抑制素在非小细胞肺癌患者中的临床治疗效果[J].中国药物与临床,2021,21(10):1731-1732.[3]沈巨信,钟波,张春意,等.吉西他滨联合顺铂治疗对老年非小细胞肺癌患者热休克蛋白90α和血管生成素-2水平的影响[J].中国老年学杂志,2018,38(21):5189-5191. [4]张涛,曹阵学,冯沁,等.重组人血管内皮抑制素治疗肺癌患者的疗效及对预后的影响[J].中国肿瘤临床与康复,2020,27(10):1173-1177.[5]奚晓丽,田天佳,郭卫东.晚期非小细胞肺癌患者重组人血管内皮抑制素联合化疗临床观察[J].中华肿瘤防治杂志,2020,27(17):1399-1403.[6]白春学,陈良安,胡成平,等.晚期非小细胞肺癌抗血管生成药物治疗中国呼吸领域专家共识(2016年版)[J].中华结核和呼吸杂志,2016,39(11):839-849.[7]张萍,艾斌.实体瘤免疫治疗疗效评价标准[J].国际肿瘤学杂志,2016,43(11):848-851.[8]李业山,林玲,陆召辉,等.重组人血管内皮抑制素持续泵入对晚期非小细胞肺癌疗效及血管生成素-2的影响[J].安徽医药,2020,24(5):1018-1022.[9]陈恩田,夏丹.重组人血管内皮抑制素联合特罗凯治疗一线化疗失败的晚期非小细胞肺癌的临床疗效[J].实用癌症杂志,2019,34(9):1553-1556.[10]郭毅,郭伟.重组人血管内皮抑制素注射液联合含铂类药物治疗晚期非小细胞肺癌的临床观察[J].实用医技杂志,2019,26(9):1186-1187.[11]李兴,马丽娜,王美清,等.重组人血管内皮抑制素靶向治疗联合DP化疗在晚期非小细胞肺癌患者中的效果研究[J].检验医学与临床,2017,14(23):3492-3494.[12]Kobayashi K,Seike M,Zou F,et al.Prognostic Significance of NSCLC and Response to EGFR-TKIs of EGFR-Mutated NSCLC Based on PD-L1 Expression[J].Anticancer Res,2018,38(2):753-762. [13]李德龙.重组人血管内皮抑制素联合顺铂胸腔热灌注治疗对晚期非小细胞肺癌患者血清促红细胞生成及其受体水平的影响[J].中国药物与临床,2019,19(10):1697-1699.[14]秦叔逵,苗静,韩宝惠,等.重组人血管内皮抑制素联合常用含铂化疗方案治疗晚期非小细胞肺癌的Ⅳ期临床研究[J].临床肿瘤学杂志,2019,24(4):289-298.[15]王卿,李崇鑫,何永梅,等.重组人血管内皮抑制素联合化疗治疗晚期非小细胞肺癌的临床观察[J].广州医科大学学报,2019,47(2):65-67.[16]陈兰.重组人血管内皮抑制素联合紫杉醇和顺铂不同给药时序治疗非小细胞肺癌的临床研究[D].泸州:西南医科大学,2014.[17]孙晓,邱春玉,杨硕,等.重组人血管内皮抑制素对晚期非小细胞肺癌患者肺功能和肿瘤标志物的影响[J].癌症进展,2019,17(15):1817-1820.[18]尤江莲,郭治,孙爱学.重组人血管内皮抑制素结合化疗治疗晚期非小细胞肺癌的疗效分析[J].中国肿瘤临床与康复,2017,24(6):704-707.[19]姜培娣,李宁,岳建,等.重组人血管内皮抑制素联合顺铂化疗治疗老年晚期非小细胞肺癌的临床疗效[J].现代生物医学进展,2017,17(13):2444-2449.[20]邢镨元,郝学志,胡兴胜,等.重组人血管内皮抑制素在晚期肺鳞癌治疗中的临床应用[J].中国肺癌杂志,2016,19(10):670-674.[21]王越希,陈晓梅,晏军,等.重组人血管内皮抑制素联合顺铂化疗方案对中晚期非小细胞肺癌患者外周血sPD-L1、CEA水平的影响[J].疑难病杂志,2016,15(5):476-478,482.

相似文献/References:

[1]田 亮,郭 楠,苗志刚,等.非小细胞肺癌中ZEB1和FoxO3a表达及意义[J].医学信息,2018,31(03):16.[doi:10.3969/j.issn.1006-1959.2018.03.006]
　TIAN Liang,GUO Nan,MIAO Zhi-gang,et al.Expression and Significance of ZEB1 and FoxO3a in Non-small Cell Lung Cancer[J].Medical Information,2018,31(04):16.[doi:10.3969/j.issn.1006-1959.2018.03.006]
[2]陶 洪,孙国平.非小细胞肺癌根治术后复发及进展影响因素的回顾性分析[J].医学信息,2018,31(12):61.[doi:10.3969/j.issn.1006-1959.2018.12.019]
　TAO Hong,SUN Guo-ping.Retrospective Analysis of Factors Influencing Recurrence and Progression after Radical Resection of Non-small Cell Lung Cancer[J].Medical Information,2018,31(04):61.[doi:10.3969/j.issn.1006-1959.2018.12.019]
[3]李春磊,裴艳志,邹志田,等.非小细胞肺癌组织中趋化因子受体CCR7的 表达及其临床意义[J].医学信息,2018,31(17):14.[doi:10.3969/j.issn.1006-1959.2018.17.004]
　LI Chun-lei,PEI Yan-zhi,ZOU Zhi-tian,et al.Expression of Chemokine Receptor CCR7 in Non-small Cell Lung Cancer and its Clinical Significance[J].Medical Information,2018,31(04):14.[doi:10.3969/j.issn.1006-1959.2018.17.004]
[4]杨 莉.TP方案联合回生口服液治疗中晚期非小细胞肺癌的疗效观察[J].医学信息,2018,31(17):17.[doi:10.3969/j.issn.1006-1959.2018.17.005]
　YANG Li.Therapeutic Effect of TP Regimen Combined with Huisheng Oral Liquid in the Treatment of Advanced Non-small Cell Lung Carcinoma[J].Medical Information,2018,31(04):17.[doi:10.3969/j.issn.1006-1959.2018.17.005]
[5]吴森林,高 斌.中性粒细胞/淋巴细胞比值与介入治疗中晚期非小细胞肺癌患者预后的相关性[J].医学信息,2019,32(03):82.[doi:10.3969/j.issn.1006-1959.2019.03.025]
　WU Sen-lin,GAO Bin.Correlation between Neutrophil/Lymphocyte Ratio and Prognosis in Patients with Advanced Non-small Cell Lung Cancer[J].Medical Information,2019,32(04):82.[doi:10.3969/j.issn.1006-1959.2019.03.025]
[6]田春琴,赵新汉,蒋冬梅,等.二线用药EGFR-TKIs治疗非选择型NSCLC疗效的Meta分析[J].医学信息,2018,31(20):49.[doi:10.3969/j.issn.1006-1959.2018.20.015]
　TIAN Chun-qin,ZHAO Xin-han,JIANG Dong-mei,et al.Meta-analysis of the Efficacy of Second-line EGFR-TKIs in the Treatment of Nonselective NSCLC[J].Medical Information,2018,31(04):49.[doi:10.3969/j.issn.1006-1959.2018.20.015]
[7]徐闻霞,陆红艳,黄 斌.胸腔镜肺叶切除和肺段切除治疗ⅠA期非小细胞肺癌的疗效比较[J].医学信息,2018,31(21):100.[doi:10.3969/j.issn.1006-1959.2018.21.027]
　XU Wen-xia,LU Hong-yan,HUANG Bin.Comparison of Thoracoscopic Lobectomy and Segmentectomy for ⅠA Non-small Cell Lung Cancer[J].Medical Information,2018,31(04):100.[doi:10.3969/j.issn.1006-1959.2018.21.027]
[8]付红星,冯小剑,彭文苗,等.康艾注射液联合化疗治疗晚期非小细胞肺癌的临床研究[J].医学信息,2018,31(24):115.[doi:10.3969/j.issn.1006-1959.2018.24.033]
　FU Hong-xing,FENG Xiao-jian,PENG Wen-miao,et al.Clinical Study of Kang'ai Injection Combined with Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer[J].Medical Information,2018,31(04):115.[doi:10.3969/j.issn.1006-1959.2018.24.033]
[9]阳 芳,黄 斌,覃超群,等.血清KL-6水平与安罗替尼治疗的非小细胞肺癌预后的关系[J].医学信息,2022,35(12):104.[doi:10.3969/j.issn.1006-1959.2022.12.025]
　YANG Fang,HUANG Bin,QIN Chao-qun,et al.Relationship Between Serum KL-6 Level and Prognosis of Non-small Cell Lung Cancer Treated with Anlotinib[J].Medical Information,2022,35(04):104.[doi:10.3969/j.issn.1006-1959.2022.12.025]
[10]贾殿军,王利军,程险峰,等.可手术的非小细胞肺癌患者外周静脉血cfDNA总浓度及长片段DNA浓度的临床价值研究[J].医学信息,2019,32(04):91.[doi:10.3969/j.issn.1006-1959.2019.04.030]
　JIA Dian-jun,WANG Li-jun,CHENG Xian-feng,et al.Clinical Value of Total cfDNA Concentration and Long Fragment DNA Concentration in Peripheral Venous Blood of Patients with Operative Non-small Cell Lung Cancer[J].Medical Information,2019,32(04):91.[doi:10.3969/j.issn.1006-1959.2019.04.030]

更新日期/Last Update: 1900-01-01